Newly developed retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is sparking considerable buzz within the weight loss community. Initial clinical research have revealed substantial losses in overall mass and gains in physiological markers for patients with obesity . Experts believe this ground-breaking approach… Read More